共 74 条
[1]
Li M(2007)Acute pancreatitis associated with sorafenib South Med J 100 909-911
[2]
Srinivas S(2004)BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099-7109
[3]
Wilhelm SM(2005)Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 965-972
[4]
Carter C(2015)Management of hepatocellular carcinoma J Cancer Res Clin Oncol 141 861-876
[5]
Tang L(2008)Sorafenib in the treatment of advanced hepatocellular carcinoma Saudi J Gastroenterol 14 40-42
[6]
Strumberg D(2010)Sorafenib-induced acute pancreatitis JOP 11 283-284
[7]
Richly H(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
[8]
Hilger RA(2007)Drug-induced acute pancreatitis: an evidence-based review Clin Gastroenterol Hepatol 5 648-661
[9]
Fitzmorris P(2007)Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 426-437
[10]
Shoreibah M(2016)Sorafenib-induced acute pancreatitis: a case report and review of the literature Intern Med 55 623-627